Pazufloxacin (INN) is a fluoroquinolone antibiotic. [1] It is sold in Japan under the brand names Pasil and Pazucross. Pazufloxacin exerts bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV, giving it potent activity against a range of Gram-negative organisms and selected Gram-positive pathogens; it has been developed as the mesylate salt for systemic use. From an analytical and formulation perspective the active pharmaceutical ingredient displays characteristic UV and mass spectral features and reproducible chromatographic retention that support HPLC and LC-MS methods for assay, related-substance determination and stability studies. Clinical formulations and local regulatory dossiers describe indications such as complicated urinary tract infections and respiratory infections in jurisdictions where the drug is authorized.
Typical API specifications for pazufloxacin set quantitative limits for impurities and related substances to meet ICH quality criteria; common control levels used in regulatory filings are individual identified impurities not greater than 0.10 percent by weight, individual unspecified impurities not greater than 0.05 percent, and total impurities not greater than 0.50 percent. Known related compounds and degradation pathways for fluoroquinolones that are monitored for pazufloxacin include N-oxide species, des-alkyl or des-ethyl degradants, decarboxylated and oxidative ring-modified products, and trace synthetic-related residues; identified related substances such as an N-oxide impurity or a des-ethyl impurity are commonly specified at about 0.10 percent or lower, while unspecified impurities are held at reporting thresholds around 0.05 percent. Residual solvents and elemental impurities are controlled separately to ICH Q3C and Q3D limits and stability-indicating HPLC or LC-MS assays are used for routine release and shelf-life testing.
Pazufloxacin is used to treat infections caused by susceptible bacteria, notably complicated urinary tract infections and certain respiratory infections in regions where it is approved; specific indications depend on local regulatory approval and prescribing information.
Pazufloxacin is generally classified as a later generation fluoroquinolone, commonly described in literature as a third generation fluoroquinolone based on its antibacterial spectrum and pharmacologic profile.
Levofloxacin is a broad-spectrum fluoroquinolone used to treat community-acquired and hospital-acquired respiratory tract infections including pneumonia, acute bacterial sinusitis and bronchitis, complicated and uncomplicated urinary tract infections, prostatitis, and certain skin and soft tissue infections when caused by susceptible organisms.
Fosfomycin is an antibacterial agent primarily used for uncomplicated lower urinary tract infections including acute cystitis; oral fosfomycin trometamol is commonly used as a single-dose treatment for cystitis, while intravenous formulations may be used for selected systemic infections and for infections caused by multidrug-resistant organisms under specialist guidance.
